Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.

Employees

1,184

Sector

Healthcare Facilities & Services

Calendar

2024-11-03 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-18	22.91 $	+0.70%	112,096
24-09-17	22.75 $	+2.94%	153,308
24-09-16	22.10 $	-1.12%	100,876
24-09-13	22.35 $	+1.54%	120,914
24-09-12	22.01 $	+1.20%	129,174

Delayed Quote Nasdaq, September 18, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

22.91USD

Average target price

27.67USD

Spread / Average Target

+20.76%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-18 pm EDT			5-day change	1st Jan Change
22.91 ^USD	+0.70%		+5.33%	-20.75%

Aug. 05	UBS Adjusts Fulgent Genetics Price Target to $27 From $25, Maintains Neutral Rating	MT
Aug. 02	Fulgent Genetics Swings to Q2 Earnings, Revenue Rises	MT

Capitalization	694M	P/E ratio 2024 *	-12.2x	P/E ratio 2025 *	-11.5x
Enterprise value	434M	EV / Sales 2024 *	-0.38x	EV / Sales 2025 *	-0.24x
Free-Float	62.29%	Yield 2024 *	-	Yield 2025 *	-

UBS Adjusts Fulgent Genetics Price Target to $27 From $25, Maintains Neutral Rating	Aug. 05	MT
Fulgent Genetics Swings to Q2 Earnings, Revenue Rises	Aug. 02	MT
Transcript : Fulgent Genetics, Inc., Q2 2024 Earnings Call, Aug 02, 2024	Aug. 02
Fulgent Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 02	CI
Earnings Flash (FLGT) FULGENT GENETICS Posts Q2 Revenue $71M, vs. Street Est of $69.1M	Aug. 02	MT
Earnings Flash (FLGT) FULGENT GENETICS Reports Q2 EPS $0.15, vs. Street Est of Loss $-0.30 Per Share	Aug. 02	MT
Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024	Aug. 02	CI
Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024	May. 03
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	May. 03	CI
Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M	May. 03	MT
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI

UBS Adjusts Fulgent Genetics Price Target to $27 From $25, Maintains Neutral Rating	Aug. 05	MT
Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	Mar. 06	MT
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	Feb. 29	MT
UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	Dec. 07	MT
Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating	23-03-02	MT

Fulgent Genetics, Inc. Stock

Equities

FLGT

US3596641098

Healthcare Facilities & Services

Valuation: Fulgent Genetics, Inc.

Chart: Fulgent Genetics, Inc.

Latest news: Fulgent Genetics, Inc.

Last Transcript: Fulgent Genetics, Inc.

Analysts' recommendations: Fulgent Genetics, Inc.

Press Releases: Fulgent Genetics, Inc.

News in other languages: Fulgent Genetics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Fulgent Genetics, Inc.

ETFs: Fulgent Genetics, Inc.

Medical & Diagnostic Laboratories

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Fulgent Reports Second Quarter 2024 Financial Results	Aug. 05	AQ
Fulgent Reports Second Quarter 2024 Financial Results	Aug. 02	BU
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024	Jul. 11	BU
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer	Jun. 03	BU
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting	May. 24	BU

Tres ETFs en la nube	22-02-02
Trois ETFs dans le cloud	22-01-31

1 day	+0.70%
1 week	+5.33%
Current month	+1.55%
1 month	-2.43%
3 months	+15.82%
6 months	+5.43%
Current year	-20.75%

Director	Title	Age	Since
James Xie FOU	Founder	58	16-05-12
Ming Hsieh CEO	Chief Executive Officer	68	16-05-12
Paul Kim DFI	Director of Finance/CFO	56	15-12-31

Name	Weight	AuM	1st Jan change	Investor Rating
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	0.30%	28 M€	+1.40%	-
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	0.26%	30 M€	+4.67%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
FULGENT GENETICS, INC.	+0.70%	+5.33%	-21.22%	-75.02%	689M
SONIC HEALTHCARE LIMITED	-1.36%	-0.33%	-11.79%	-35.56%	8.85B
RADNET, INC.	+0.45%	+7.72%	+139.51%	+134.57%	4.94B
DR. LAL PATHLABS LIMITED	+0.81%	-4.68%	+34.83%	-17.46%	3.22B
NEOGENOMICS, INC.	-0.80%	-0.92%	+23.55%	-66.56%	2.09B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-3.04%	-5.61%	-56.94%	-72.46%	1.76B
FLEURY S.A.	-0.36%	+0.12%	+13.46%	-27.39%	1.65B
METROPOLIS HEALTHCARE LIMITED	-2.14%	-1.54%	+42.68%	-32.11%	1.31B
JIANGXI RIMAG GROUP CO., LTD.	-2.74%	+30.71%	-	-	1.25B
Average	-0.96%	+5.00%	+20.51%	-24.00%	2.86B
Weighted average by Cap.	-0.82%	+3.94%	+28.97%	-4.53%

Manager	Title	Age	Since
Ming Hsieh CEO	Chief Executive Officer	68	16-05-12
Linda Marsh BRD	Director/Board Member	74	19-07-31
Michael Nohaile BRD	Director/Board Member	55	22-07-31

	2024 *	2025 *
Net sales	282M	322M
Net income	-58.01M	-62.34M
Net Debt	-801M	-773M